How are CYP2C19 and Wechseljahre related?

CYP2C19 is a liver enzyme responsible for metabolizing many drugs, including certain antidepressants (e.g., citalopram), proton pump inhibitors, and clopidogrel. During menopause (Wechseljahre), hormonal shifts may influence CYP2C19 activity, but the evidence is limited and mostly mechanistic. Some research suggests estrogen can modulate CYP2C19, potentially affecting drug efficacy and tolerability in menopausal women. However, a direct link between CYP2C19 variants and menopausal symptoms is not established. Genetic testing for CYP2C19 (e.g., *2, *3, *17) can indicate metabolizer status, but its clinical utility for menopause management remains unclear. The evidence is weak, based on pharmacological reasoning rather than robust clinical trials. Be cautious of marketing claims: a DNA test cannot replace medical advice for hormone therapy or symptom management during menopause.